|Description||CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro, consistent with AKT inhibition.|
|Synonyms||CCT128930; CCT-128930; CCT 128930|
|Current Developer||Cancer Research UK Centre for Cancer Therapeutics|
AKT inhibitor VIII
Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and...
FPA 124 is an Akt/PKB inhibitor (IC50 = 100 nM) that inhibits cell proliferation in various cancer cell lines in vitro and decreases NF-κB activity and tumor lo...
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increas...
CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine co...
Crosstide, a peptide analog of glycogen synthase kinase α/β fusion protein sequence, acts as a substrate for Akt (PKB) (Km=4µM) and is useful in phosphocellulos...
PF-AKT400 is an APT competitor inhibitor of AKR kinase. This compound was first described as compound 42 in J. Med. Chem. 2010, 53, 4615–4622 by a group of Pfi...
LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...
Akt1 and Akt2-IN-1
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is depend...